IMOGAM RABIES-HT (Sanofi Pasteur Inc.)
Welcome to the PulseAid listing for the IMOGAM RABIES-HT drug offered from Sanofi Pasteur Inc.. This pharmaceutical is classified as a PLASMA DERIVATIVE. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same PLASMA DERIVATIVE drug type category.
| LABELER NAME / MANUFACTURER: | Sanofi Pasteur Inc. |
| NON-PROPRIETARY NAME: | HUMAN RABIES VIRUS IMMUNE GLOBULIN |
| SUBSTANCE NAME: | HUMAN RABIES VIRUS IMMUNE GLOBULIN |
| TYPE: | PLASMA DERIVATIVE |
| PHARMA CLASS: | |
| ROUTE: | INTRAMUSCULAR |
| DOSAGE FORM: | INJECTION, SOLUTION |
| MARKETING CATEGORY NAME: | BLA |
| START MARKETING DATE: | 1984-04-27 |
| END MARKETING DATE: | 0000-00-00 |
IMOGAM RABIES-HT PLASMA DERIVATIVE Details:
| Item Description | IMOGAM RABIES-HT from Sanofi Pasteur Inc. |
| LABELER NAME: | Sanofi Pasteur Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 150([iU]/mL) |
| START MARKETING DATE: | 1984-04-27 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 49281-190_0554e76f-a5a3-4480-998c-62bd4e40c0b8 |
| PRODUCT NDC: | 49281-190 |
| APPLICATION NUMBER: | BLA103932 |
Other HUMAN RABIES VIRUS IMMUNE GLOBULIN Pharmaceutical Manufacturers / Labelers:
